Foghorn Therapeutics Inc. (FHTX)
FHTX Stock Price Chart
Explore Foghorn Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze FHTX price movements and trends.
FHTX Company Profile
Discover essential business fundamentals and corporate details for Foghorn Therapeutics Inc. (FHTX) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
23 Oct 2020
Employees
112.00
Website
https://foghorntx.comCEO
Adrian H. Gottschalk
Description
Foghorn Therapeutics Inc. is a clinical-stage biopharmaceutical company dedicated to discovering and developing medicines. Their focus is on addressing genetically determined vulnerabilities within the chromatin regulatory system. The company employs its exclusive "Gene Traffic Control" platform to pinpoint, validate, and strategize drug development for specific targets within this complex system. Its pipeline includes FHD-286, a small-molecule agent engineered to halt the enzymatic activity of BRG1 and BRM. This compound is being developed to treat metastatic uveal melanoma, as well as acute myeloid leukemia and myelodysplastic syndrome that have either recurred or are resistant to previous therapies. Another key candidate, FHD-609, is a small-molecule protein degrader designed to target BRD9, intended for patients diagnosed with synovial sarcoma. Beyond these, Foghorn is also further developing a selective enzymatic inhibitor and a protein degrader, both designed to modulate BRM. Additionally, they are working on ARID1B selective modulators, with potential applications in treating ovarian, endometrial, colorectal, bladder, and gastric cancers. The company has forged strategic alliances, including a research collaboration and licensing agreement with Merck Sharp & Dohme Corp. aimed at unearthing and creating novel oncology therapies focused on a transcription factor target. They also collaborate with Loxo Oncology to devise new cancer treatments. Foghorn Therapeutics Inc. was established in 2015 and maintains its headquarters in Cambridge, Massachusetts.
FHTX Financial Timeline
Browse a chronological timeline of Foghorn Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 Aug 2026
EPS estimate is -$0.23, while revenue estimate is $7.05m.
Earnings released on 7 May 2026
EPS came in at -$0.29 falling short of the estimated -$0.28 by -3.57%, while revenue for the quarter reached $3.27m , missing expectations by -58.86%.
Earnings released on 11 Mar 2026
EPS came in at -$0.34 falling short of the estimated -$0.28 by -21.43%, while revenue for the quarter reached $9.25m , missing expectations by -8.91%.
Earnings released on 5 Nov 2025
EPS came in at -$0.25 surpassing the estimated -$0.31 by +19.35%, while revenue for the quarter reached $8.15m , missing expectations by -14.18%.
Earnings released on 5 Aug 2025
EPS came in at -$0.28 surpassing the estimated -$0.31 by +9.68%, while revenue for the quarter reached $7.56m , missing expectations by -7.54%.
Earnings released on 14 May 2025
EPS came in at -$0.30 matching the estimated -$0.30, while revenue for the quarter reached $5.95m , missing expectations by -4.61%.
Earnings released on 6 Mar 2025
EPS came in at -$0.30 surpassing the estimated -$0.43 by +30.23%, while revenue for the quarter reached $2.86m , missing expectations by -67.06%.
Earnings released on 4 Nov 2024
EPS came in at -$0.31 surpassing the estimated -$0.42 by +26.19%, while revenue for the quarter reached $7.81m , missing expectations by -4.03%.
Earnings released on 8 Aug 2024
EPS came in at -$0.45 surpassing the estimated -$0.60 by +25.00%, while revenue for the quarter reached $6.89m , beating expectations by +14.04%.
Earnings released on 6 May 2024
EPS came in at -$0.59 falling short of the estimated -$0.55 by -7.27%, while revenue for the quarter reached $5.05m , missing expectations by -26.92%.
Earnings released on 7 Mar 2024
EPS came in at -$0.57 surpassing the estimated -$0.79 by +27.85%, while revenue for the quarter reached $5.77m , beating expectations by +24.87%.
Earnings released on 2 Nov 2023
EPS came in at -$0.34 surpassing the estimated -$0.72 by +52.78%, while revenue for the quarter reached $17.48m , beating expectations by +278.31%.
Earnings released on 4 Aug 2023
EPS came in at -$0.70 surpassing the estimated -$0.73 by +4.11%, while revenue for the quarter reached $5.60m , missing expectations by -10.56%.
Earnings released on 8 May 2023
EPS came in at -$0.73 falling short of the estimated -$0.68 by -7.35%, while revenue for the quarter reached $5.31m , missing expectations by -15.19%.
Earnings released on 9 Mar 2023
EPS came in at -$0.69 falling short of the estimated -$0.59 by -16.95%, while revenue for the quarter reached $4.18m , missing expectations by -16.98%.
Earnings released on 8 Nov 2022
EPS came in at -$0.62 falling short of the estimated -$0.60 by -3.33%, while revenue for the quarter reached $6.63m , missing expectations by -21.77%.
Earnings released on 9 Aug 2022
EPS came in at -$0.66 falling short of the estimated -$0.53 by -24.53%, while revenue for the quarter reached $4.49m , missing expectations by -53.15%.
Earnings released on 9 May 2022
EPS came in at -$0.65 falling short of the estimated -$0.40 by -62.50%, while revenue for the quarter reached $3.92m , missing expectations by -58.43%.
Earnings released on 10 Mar 2022
EPS came in at -$0.77 falling short of the estimated -$0.74 by -4.05%, while revenue for the quarter reached $713.00k , beating expectations by +0.46%.
Earnings released on 9 Nov 2021
EPS came in at -$0.71 falling short of the estimated -$0.66 by -7.58%, while revenue for the quarter reached $41.00k , missing expectations by -83.60%.
Earnings released on 10 Aug 2021
EPS came in at -$0.63 matching the estimated -$0.63, while revenue for the quarter reached $279.00k , meeting expectations.
FHTX Stock Performance
Access detailed FHTX performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
